Unixell Biotech Receives FDA IND Clearance for UX-GIP001 iPSC-Derived Cell Therapy for Focal Epilepsy

On March 12, 2026, Unixell Biotech received FDA Investigational New Drug (IND) clearance for UX-GIP001, marking it as the first iPSC-derived allogeneic epilepsy cell therapy approved in the U.S.1

UX-GIP001 also establishes Unixell as China's first company to advance a cell therapy for epilepsy into the clinical stage1

The therapy works by producing inhibitory neural progenitor cells that reconstruct inhibitory circuits and suppress seizures in patients with impaired GABAergic interneurons1

Preclinical studies demonstrated UX-GIP001's efficacy in epileptic animal models and confirmed its safety profile1

A Phase 1 clinical trial is planned to evaluate the safety, tolerability, and efficacy of UX-GIP001 for drug-resistant epilepsy patients1

Unixell Biotech was established in 2021 and specializes in cell therapy drugs for neurological diseases, with a pipeline targeting both Parkinson's disease and epilepsy1

The company has secured financing from major investors including Hillhouse Capital, CDH Investments, Fosun Group, and Sherpa Healthcare Partners1

Sources:

1. https://www.biospace.com/press-releases/unixell-biotech-receives-ind-clearance-by-fda-for-its-allogeneic-ipsc-derived-cell-therapy-ux-gip001-for-focal-epilepsy